Table 2A.
Patient characteristics and acute toxicity (CTCAE)
| Characteristics and toxicity | GIT 1992, n (%) | GIT 1996, n (%) | Total, n (%) |
|---|---|---|---|
| Patients with intestinal lymphoma | 38 (28.4) | 96 (71.6) | 134 (100) |
| Age, median (range), years | 53 (19–81) | 60 (18–72) | 58 (18–81) |
| Gender | |||
| Female | 13 (34.2) | 30 (31.3) | 43/134 (32.1) |
| Male | 25 (65.8) | 66 (68.8) | 91/134 (67.9) |
| Histology | |||
| Indolent | 7 (18.4) | 44 (45.8) | 51/134 (38.1) |
| Aggressive | 26 (68.4) | 45 (46.9) | 71/134 (53.0) |
| Aggressive/indolent | 5 (13.2) | 7 (7.3) | 12/134 (9.0) |
| Primary localization | |||
| Duodenal | 1/38 (2.6) | 12/96 (12.5) | 13/134 (9.7) |
| Small bowel | 10/38 (26.3) | 23/96 (24.0) | 33/134 (24.6) |
| Ileocecal | 16/38 (42.1) | 30/96 (31.3) | 46/134 (34.3) |
| Colonic | 1/38 (2.6) | 8/96 (8.3) | 9/134 (6.7) |
| Rectal | 3/38 (7.9) | 6/96 (6.3) | 9/134 (6.7) |
| Multilocular intestinal | 7/38 (18.4) | 17/96 (17.7) | 24/134 (17.9) |
| Ann Arbor stage | |||
| IE | 11 (28.9) | 42 (43.8) | 53/134 (39.6) |
| II1E | 14 (36.8) | 30 (31.3) | 44/134 (32.8) |
| II2E | 13 (43.2) | 20 (20.8) | 33/134 (24.6) |
| III | — | 2 (2.1) | 2/134 (1.5) |
| IV | — | 2 (2.1) | 2/134 (1.5) |
| Resection | |||
| Total | 32/38 (84.2) | 58/96 (60.4) | 90/134 (67.2) |
| Indolent | 6/38 (15.8) | 18/96 (18.8) | 34/134 (25.4) |
| Aggressive | 23/38 (60.5) | 35/96 (36.5) | 58/134 (43.3) |
| Aggressive/indolent | 3/38 (7.9) | 5/96 (5.2) | 8/134 (6.0) |
| Chemotherapy | |||
| Total | 31/38 (81.6) | 58/96 (60.4) | 89/134 (66.4) |
| Indolent | 1/38 (2.6) | 6/96 (6.3) | 7/134 (5.2) |
| Aggressive | 26/38 (68.4) | 45/96 (46.9) | 71/134 (53.0) |
| Aggressive/indolent | 4/38 (10.5) | 7/96 (7.3) | 11/134 (8.2) |
| Complete remission | 38 (100) | 96 (100) | 134 (100) |
| ECOG score | |||
| ECOG 0 | 32/38 (84.2) | 88/96 (91.7) | 120/134 (89.6) |
| ECOG 1 | 4/38 (10.5) | 8/96 (8.3) | 12/134 (8.9) |
| ECOG 2 | 1/38 (2.6) | — | 1/134 (0.7) |
| ECOG 3 | 1/38 (2.6) | — | 1/134 (0.7) |
| Acute toxicity, CTCAE | |||
| Drop in hemoglobin | |||
| 0 | 27/38 (71.1) | 72/96 (75.0) | 99/134 (73.9) |
| 1–2 | 11/38 (28.9) | 21/96 (21.9) | 32/134 (23.9) |
| 3–4 | — | 3/96 (3.1) | 3/134 (2.2) |
| Leukocytopenia | |||
| 0 | 19/38 (50.0) | 34/96 (35.4) | 53/134 (39.6) |
| 1–2 | 15/38 (39.5) | 58/96 (60.4) | 73/134 (54.5) |
| 3–4 | 4/38 (10.5) | 4/96 (4.2) | 8/134 (6.0) |
| Thrombocytopenia | |||
| 0 | 28/38 (73.7) | 67/96 (69.8) | 95/134 (70.9) |
| 1–2 | 8/38 (21.1) | 27/96 (28.1) | 35/134 (26.1) |
| 3–4 | 2/38 (5.3) | 2/96 (2.1) | 4/134 (3.0) |
| Elevated bilirubina | |||
| 0 | 36/38 (94.7) | 88/96 (91.7) | 124/134 (92.5) |
| 1–2 | 2/38 (5.3) | 4/96 (4.2) | 6/134 (4.5) |
| 3–4 | — | — | — |
| Elevated transaminasesa | |||
| 0 | 38/38 (100.0) | 82/96 (85.4) | 120/134 (89.6) |
| 1–2 | — | 9/96 (9.4) | 9/134 (6.7) |
| 3–4 | — | 1/96 (1.0) | 1/134 (0.7) |
| Loss of appetiteb | |||
| 0 | 22/38 (57.9) | 48/96 (50.0) | 70/134 (52.2) |
| 1–2 | 15/38 (39.5) | 42/96 (43.8) | 57/134 (42.5) |
| 3–4 | 1/38 (2.6) | 5/96 (5.2) | 6/134 (4.5) |
| Weight lossb | |||
| 0 | 26/38 (68.4) | 57/96 (59.4) | 83/134 (61.9) |
| 1–2 | 12/38 (31.6) | 38/96 (39.6) | 50/134 (37.3) |
| 3–4 | — | — | — |
| Nauseab | |||
| 0 | 16/38 (42.1) | 42/96 (43.8) | 58/134 (43.3) |
| 1–2 | 14/38 (36.8) | 28/96 (29.2) | 42/134 (31.3) |
| 3–4 | 8/38 (21.1) | 25/96 (26.0) | 33/134 (24.6) |
| Diarrheab | |||
| 0 | 17/38 (44.7) | 35/96 (36.5) | 52/134 (38.8) |
| 1–2 | 7/38 (18.4) | 37/96 (38.5) | 44/134 (32.8) |
| 3–4 | 14/38 (36.8) | 23/96 (24.0) | 37/134 (27.6) |
| Constipationb | |||
| 0 | 37/38 (97.4) | 90/96 (93.8) | 127/134 (94.8) |
| 1–2 | — | 5/96 (5.2) | 5/134 (3.7) |
| 3–4 | 1/38 (2.6) | — | 1/134 (0.7) |
The available numbers are given, with missing data being the difference between total numbers and given numbers.
a
Acute toxicity (CTCAE) missing four patients (4.2%) from GIT 1996 in total 4 of 134 patients (3.0%) because of missing evaluation of the parameters “bilirubin” and “elevated transaminases.”
b
Acute toxicity (CTCAE) missing one patient (1.0%) from GIT 1996, in total 1 of134 patients (0.7%) because of missing evaluation of the parameters “clinical symptoms.”
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); ECOG Eastern Cooperative Oncology Group.